0.6665

2.70% 0.0175

After Hours: .67 0.0035 +0.53%

Outlook Therapeutics Inc (OTLK)

Overview News Price History Financials Discussions Forecast Stock Split

Outlook Therapeutics Inc stock is traded at $0.6665, with a volume of 6.35M. It is up +2.70% in the last 24 hours and down -30.59% over the past month. Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Previous Close:

$0.649

Open:

$0.6599

24h Volume:

6.35M

Relative Volume:

0.37

Market Cap:

$161.74M

Revenue:

$424.90K

Net Income/Loss:

$-94.02M

P/E Ratio:

-0.2683

EPS:

-2.4842

Net Cash Flow:

$-51.25M

1W Performance:

+3.35%

1M Performance:

-30.59%

6M Performance:

+52.00%

1Y Performance:

-24.96%

1-Day Range:

$0.6451

$0.6962

1-Week Range:

$0.6043

$0.6962

52-Week Range:

$0.1611

$2.5375

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name

Outlook Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(609) 619-3990

Address

111 S. WOOD AVENUE, ISELIN, NJ

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

OTLK's Discussions on Twitter

Compare OTLK vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OTLK Outlook Therapeutics Inc	0.6665	164.12M	424.90K	-94.02M	-51.25M	-2.4842
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-25	Downgrade	Guggenheim	Buy → Neutral
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight
Apr-03-23	Initiated	Guggenheim	Buy
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-22	Initiated	BTIG Research	Buy
Sep-13-22	Initiated	Chardan Capital Markets	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
May-16-19	Initiated	Oppenheimer	Outperform
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

Sep 06, 2026

These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits

Sep 06, 2026

Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits

Sep 06, 2026

OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits

Sep 06, 2026

OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits

Sep 06, 2026

Sep 05, 2026

Outlook Therapeutics Stock Price Forecast. Should You Buy OTLK? - StockInvest.us

Sep 05, 2026

Sep 03, 2026

People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - BioBuzz

Sep 03, 2026

Sep 02, 2026

CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan

Sep 02, 2026

Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - Stock Titan

Sep 02, 2026

Aug 28, 2026

Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail

Aug 28, 2026

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm

Aug 28, 2026

Lundquist appointed chief financial officer at Outlook Therapeutics of Iselin - ROI-NJ

Aug 28, 2026

Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - visionmonday.com

Aug 28, 2026

Aug 27, 2026

Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026 - marketscreener.com

Aug 27, 2026

Aug 20, 2026

OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record - Stocktwits

Aug 20, 2026

Aug 19, 2026

Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo

Aug 19, 2026

Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan

Aug 19, 2026